Genetically modified organisms to remediate polychlorinated biphenyls. Where do we stand?

被引:21
|
作者
Sylvestre, M [1 ]
机构
[1] INRS, Inst Armand Frappier, Pointe Claire, PQ H9R 1G6, Canada
关键词
PCB; dioxygenase; engineering catabolic pathway;
D O I
10.1016/j.ibiod.2004.03.011
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The biphenyl catabolic pathway transforms selected polychlorinated biphenyls (PCBs) to chlorobenzoates. The inability of bacteria to degrade the persistent PCBs is due to failure of enzymes of this pathway to catalyze their transformation. Biphenyl 2,3-dioxygenase (BPDO), 2,3-dihydroxybiphenyl 1,2-dioxygenase (HPDO) and 2-hydroxy-6-oxo-6-phenyl-2,4-hexadienoate (HOPDA) hydrolase (HOPDAH) are critical to deten-nine the range of PCBs degraded. Investigations are under way to examine features of these enzymes that influence their interactions with chlorinated substrates and to propose ways to bypass the blockages that they cause. BPDO terminal oxygenase component is an hexamer comprised of an alpha and a beta subunit. Burkholderia sp. LB400 and Pseudomonas pseudoalcaligenes KF707 BPDOs are very similar but exhibit quite distinct substrate specificities. Comainonas testosteroni B-356 and Rhodoccocus globerulus P6 BPDOs are more distantly related to LB400 BPDO and show a different range of PCB substrate used. Comparative analyses of the catalytic properties of chimeras of these enzymes unrevealed several regions of the C-terminal domain of the alpha subunit that strongly influence BPDO's substrate specificity. DNA shuffling between genes encoding these homologous BPDOs has been used to broaden the enzyme's substrate specificity. HPDOs are unable to oxygenate 3,4-dihydroxylated metabolites of chlorobiphenyls. HOPDAH are limited in their capacity to hydrolyze HOPDAs bearing chloro substituents on the dienoate inoiety. Enzymes homologous to HPDO and HOPDAH but exhibiting different patterns of substrate specificity have been identified. They provide tools to examine the enzymes structural features responsible for substrate specificity and to plan strategies to extend the range of chlorinated substrates that they can transforrn. (C) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:153 / 162
页数:10
相关论文
共 50 条
  • [21] Where do we stand on econophysics?
    Carbone, A.
    Kaniadakis, G.
    Scarfone, A. M.
    PHYSICA A-STATISTICAL MECHANICS AND ITS APPLICATIONS, 2007, 382 (01) : XI - XIV
  • [22] Delirium: Where do we stand?
    Pae C.-U.
    Marks D.M.
    Han C.
    Patkar A.A.
    Masand P.
    Current Psychiatry Reports, 2008, 10 (3) : 240 - 248
  • [23] WHERE DO WE STAND WITH PPIS
    WELSH, JS
    AMERICAN PHARMACY, 1979, 19 (12): : 12 - 14
  • [24] Hyperfractionation: Where do we stand?
    BeckBornholdt, HP
    Dubben, HH
    LiertzPetersen, C
    Willers, H
    RADIOTHERAPY AND ONCOLOGY, 1997, 43 (01) : 1 - 21
  • [25] WHERE DO WE STAND ON METRIFICATION
    KIRCHER, KF
    DESIGN NEWS, 1969, 24 (02) : 1 - &
  • [26] Tuberculosis: Where do we stand?
    Becx-Bleumink, M
    Broekmans, JF
    TROPICAL MEDICINE & INTERNATIONAL HEALTH, 1998, 3 (06) : 423 - 424
  • [27] Reflections on "Where Do We Stand?"
    Mccaslin, Richard B.
    CIVIL WAR HISTORY, 2014, 60 (04) : 407 - 408
  • [28] Biomarkers, Where Do We Stand
    Dixit, Vikash
    Sharma, Payal
    Dhage, Atul Dyandeo
    INDIAN JOURNAL OF PSYCHIATRY, 2015, 57 (05) : S165 - S166
  • [29] TUBERCULOSIS - WHERE DO WE STAND
    HOLGUIN, AH
    JOURNAL OF THE AMERICAN COLLEGE OF HEALTH ASSOCIATION, 1968, 17 (02): : 175 - 178
  • [30] QCD - WHERE DO WE STAND
    ALTARELLI, G
    MULTIPARTICLE DYNAMICS 1988, 1988, : 253 - 253